natgillin/translations-raw huggingface dataset:
From a microbiological point of view, the medicinal product should be used immediately.
Z mikrobiološkega stališča je treba zdravilo uporabiti takoj po pripravi.
Please talk to your doctor or pharmacist if you are taking any of the following medicines:
Obvestite zdravnika ali farmacevta, če jemljete katero koli od naslednjih zdravil:
†Difference and confidence interval (CI) were calculated using the method proposed by Miettinen and Nurminen and adjusted for gender.
†Razlika in interval zaupanja (IZ) sta bila izračunana z uporabo metode po Miettinenu in Nurminenu in sta bila prilagojena glede na spol.
In the event of overdose, fosaprepitant should be discontinued and general supportive treatment and monitoring should be provided.
V primeru prevelikega odmerjanja je treba dajanje fosaprepitanta prekiniti in uvesti splošno podporno zdravljenje ter nadzor.
A summary of the primary and secondary endpoints is shown in Table 7.
Povzetek primarnih in sekundarnih opazovanih dogodkov je prikazan v preglednici 7.
Frequencies are defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000) and very rare (<1/10,000), not known (cannot be estimated from the available data).
Pogostnost je opredeljena kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
This effect was not considered clinically important.
Ta učinek ni veljal za klinično pomembnega.
CYP3A4 interactions
Interakcije s CYP3A4
The safety and efficacy of IVEMEND in infants below 6 months of age have not been established.
Varnost in učinkovitost zdravila IVEMEND pri dojenčkih, mlajših od 6 mesecev, nista bili dokazani.
Complete response† Delayed phase‡ Complete response† Overall§
Popoln odziv† Zapoznela faza‡ Popoln odziv† Celotna faza§ Akutna faza§§
Occupancy of brain NK1 receptors, in this study, correlate well with aprepitant plasma concentrations.
Zasedenost možganskih receptorjev NK1 v tej študiji je v dobri korelaciji s plazemskimi koncentracijami aprepitanta.
Although a 32 mg intravenous dose of ondansetron was used in clinical trials, this is no longer the recommended dose.
Čeprav se je v kliničnih preskušanjih uporabljal 32 mg intravenski odmerek ondansetrona, to ni več priporočeni odmerek.
If you are pregnant or breast-feeding, may be pregnant or are planning to have a baby, ask your doctor for advice before receiving this medicine.
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom, preden boste prejeli to zdravilo.
For information regarding birth control, see ‘Other medicines and IVEMEND'.
Za podatke glede kontracepcije glejte "Druga zdravila in zdravilo IVEMEND".
IVEMEND works by blocking signals to that area, thereby reducing nausea and vomiting.
Zdravilo IVEMEND deluje tako, da blokira signale v to področje, s čimer zmanjšuje navzeo in bruhanje.
Gently invert the bag 2-3 times (see ‘How to use IVEMEND').
Vrečko 2 do 3 krat nežno obrnite (glejte "Kako uporabljati zdravilo IVEMEND").
If signs or symptoms of local irritation occur, the injection or infusion should be terminated and restarted in another vein.
Če se pojavijo znaki ali simptomi lokalnega draženja, je treba injiciranje ali infundiranje prekiniti in zdravilo aplicirati v drugo veno.
Efficacy was based on evaluation of the following composite measures: complete response in both the overall and delayed phases and no vomiting in the overall phase.
Učinkovitost zdravljenja je temeljila na oceni naslednjih sestavljenih meril: popoln odziv v celotni in zapozneli fazi in brez bruhanja v celotni fazi.
Do not give IVEMEND to children under 6 months of age or who weigh less than 6 kg, because it has not been studied in this population.
Zdravila IVEMEND ne dajajte otrokom, mlajšim od 6 mesecev ali s telesno maso manj kot 6 kg, ker pri tej populaciji zdravilo ni bilo raziskano.
EU/1/07/437/003 1 x 1 vial EU/1/07/437/004 1 x 10 vials
EU/1/07/437/003 1 x 1 viala EU/1/07/437/004 1 x 10 vial
Highly Emetogenic Chemotherapy (HEC)
Zelo emetogena kemoterapija (HEC)
The contribution of fosaprepitant to the overall antiemetic effect has not fully been characterised, but a transient contribution during the initial phase cannot be ruled out.
Prispevek fosaprepitanta k skupnemu antiemetičnemu delovanju ni povsem pojasnjen, vendar pa prehodnega učinka med uvodno fazo ni možno izključiti.
Pharmacotherapeutic group: Antiemetics and antinauseants, ATC code: A04AD12.
Farmakoterapevtska skupina: Antiemetiki in zdravila proti slabosti, oznaka ATC: A04AD12.
Therefore, the recommendations for use of IVEMEND with other medicinal products in paediatric patients are based upon adult data from fosaprepitant and aprepitant studies.
Zato priporočila za uporabo zdravila IVEMEND z drugimi zdravili pri pediatričnih bolnikih temeljijo na podatkih iz študij fosaprepitanta in aprepitanta pri odraslih.
It belongs to a group of medicines called "neurokinin 1 (NK1) receptor antagonists".
Spada v skupino zdravil, imenovanih "antagonisti receptorjev za nevrokinin 1 (NK1)".
The potential effects on reproduction of alterations in neurokinin regulation are unknown.
Možni učinki zaradi sprememb regulacije nevrokininov na sposobnost razmnoževanja niso znani.
Aprepitant is not excreted unchanged in urine.
Aprepitant se ne izloča z urinom v nespremenjeni obliki.
P-Value
p-vrednost
These hypersensitivity reactions have generally responded to discontinuation of the infusion and administration of appropriate therapy.
Te preobčutljivostne reakcije so se običajno odzvale na prekinitev infuzije in ustrezno zdravljenje.
The estimated time to first emesis is depicted by the Kaplan-Meier plot in Figure 1.
Ocenjeni čas do prvega bruhanja prikazuje Kaplan-Meierjeva krivulja na Sliki 1.
Therefore, there is no evidence of interaction with the use of IVEMEND 150 mg and 5-HT3 antagonists.
Zato ni dokazov o medsebojnem delovanju pri uporabi zdravila IVEMEND 150 mg in antagonistov 5-HT3.
Other medicines and IVEMEND
Druga zdravila in zdravilo IVEMEND
1-Day Regimen of Fosaprepitant in Adults
1-dnevna shema fosaprepitanta pri odraslih
It is not known whether IVEMEND is excreted in human milk; therefore, breast-feeding is not recommended during treatment with this medicine.
Ni znano, ali se zdravilo IVEMEND izloča v materino mleko, zato med zdravljenjem s tem zdravilom dojenje ni priporočljivo.
The efficacy of fosaprepitant was evaluated based on the primary and secondary endpoints listed in Table 8 and was shown to be superior to the control regimen with regard to complete response in the delayed and overall phases.
Učinkovitost fosaprepitanta je bila ocenjena na osnovi primarnih in sekundarnih opazovanih dogodkov, navedenih v preglednici 8, in se je izkazala za boljšo od kontrolne sheme zdravljenja glede na popoln odziv v zapozneli in celotni fazi.
It is not known whether aprepitant is excreted in human milk.
Ni znano, ali se aprepitant izloča v materino mleko.
For additional information on the co-administration with corticosteroids, see section 4.5.
Za dodatne podatke o sočasni uporabi s kortikosteroidi glejte poglavje 4.5.
Aprepitant is highly protein bound, with a mean of 97 %.
Aprepitant se močno veže na beljakovine, povprečno 97 %.
A population pharmacokinetic analysis of aprepitant in paediatric patients (aged 6 months through 17 years) suggests that gender and race have no clinically meaningful effect on the pharmacokinetics of aprepitant.
Analiza populacijske farmakokinetike aprepitanta pri pediatričnih bolnikih (starih od 6 mesecev do 17 let) kaže, da spol in rasa nimata klinično pomembnega vpliva na farmakokinetiko aprepitanta.
What you need to know before you use IVEMEND
Kaj morate vedeti, preden boste prejeli zdravilo IVEMEND
The safety profile of fosaprepitant in adult and paediatric patients was generally similar to that observed with aprepitant.
Varnostni profil fosaprepitanta pri odraslih in pediatričnih bolnikih je bil na splošno podoben tistemu za aprepitant.
Haemodialysis conducted 4 or 48 hours after dosing had no significant effect on the pharmacokinetics of aprepitant; less than 0.2 % of the dose was recovered in the dialysate.
Hemodializa, izvedena 4 ali 48 ur po odmerjanju, ni pomembno vplivala na farmakokinetiko aprepitanta; v dializatu se je izločilo manj kot 0,2 % odmerka.
Rifampicin decreased the mean terminal half-life of oral aprepitant by 68 %.
Rifampicin je zmanjšal povprečni končni razpolovni čas peroralnega aprepitanta za 68 %.
Before treatment with this medicine, tell your doctor if you have liver disease because the liver is important in breaking down the medicine in the body.
Pred zdravljenjem s tem zdravilom obvestite zdravnika, če imate bolezen jeter, ker jetra sodelujejo pri presnovi zdravila v telesu.
IVEMEND should not be used during pregnancy unless clearly necessary.
Zdravila IVEMEND se ne sme uporabljati med nosečnostjo, razen če je nujno potrebno.
Additionally, concomitant administration with irinotecan should be approached with particular caution as the combination might result in increased toxicity.
Poleg tega je previdnost še posebej potrebna pri sočasni uporabi irinotekana, saj se lahko pri sočasni uporabi poveča toksični učinek.
IVEMEND may have minor influence on the ability to drive and use machines.
Zdravilo IVEMEND ima lahko blag vpliv na sposobnost vožnje in upravljanja strojev.
Aprepitant is a selective high-affinity antagonist at human substance P neurokinin 1 (NK1) receptors.
Aprepitant je selektivni antagonist z veliko afiniteto na humanih receptorjih za substanco P nevrokinin 1 (NK1).
Stop taking IVEMEND and see a doctor immediately if you notice any of the following side effects, which may be serious, and for which you may need urgent medical treatment: - Hives, rash, itching, difficulty breathing or swallowing, or a serious decrease of blood pressure (frequency not known, cannot be estimated from the available data); these are signs of a serious allergic reaction.
Prenehajte jemati zdravilo IVEMEND in pojdite takoj k zdravniku, če opazite katerega od naslednjih neželenih učinkov, ki so lahko resni in zaradi katerih boste lahko nujno potrebovali zdravljenje: - koprivnico, izpuščaj, srbenje, težave z dihanjem ali požiranjem, ali občutno znižanje krvnega tlaka (neznana pogostnost, ni je mogoče oceniti iz razpoložljivih podatkov); to so znaki hude alergijske reakcije.
80 mg intravenously OR 80 mg orally (EMEND capsules)
80 mg intravensko ALI 80 mg peroralno (kapsule EMEND)
• Volume to administer (ml) equals the recommended dose (mg)
• Količina za apliciranje (ml) je enaka priporočenemu odmerku (mg)
However, it should be noted that the value of the toxicity studies carried out with rodents, rabbits and monkeys, including the reproduction toxicity studies, are limited since systemic exposures to fosaprepitant and aprepitant were only similar or even lower than therapeutic exposure in adult humans.
Vendar pa je treba izpostaviti, da je vrednost študij toksičnosti, izvedenih na glodavcih, kuncih in opicah, vključno s študijami vplivov na sposobnost razmnoževanja, omejena, saj je bila sistemska izpostavljenost fosaprepitantu in aprepitantu le podobna ali celo manjša od sistemske izpostavljenosti pri odraslih ljudeh pri uporabi terapevtskih odmerkov.
Discard any remaining solution and waste material.
Vso preostalo raztopino in odpadni material zavrzite.
For fosaprepitant and aprepitant no clinical data on exposed pregnancies are available.
Za fosaprepitant in aprepitant ni na voljo kliničnih podatkov za nosečnice, ki so bile izpostavljene zdravilu.
This medicine should not be used during pregnancy unless clearly necessary.
Med nosečnostjo se tega zdravila ne sme uporabljati, če to ni nujno potrebno.
Moderately Emetogenic Chemotherapy (MEC)
Zmerno emetogena kemoterapija (MEC)
IVEMEND contains sodium This medicine contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodium- free'.
Zdravilo IVEMEND vsebuje natrij To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na odmerek, kar v bistvu pomeni "brez natrija".
Data are lacking regarding effects on CYP2C8 and CYP2C19.
Podatki o učinkih na CYP2C8 in CYP2C19 niso na voljo.
There were no margins to clinically relevant exposure of aprepitant.
Meje za klinično pomembno izpostavljenost aprepitantu ni bilo.
For short term treatment, these findings are considered unlikely to be clinically relevant.
Za kratkotrajno uporabo ti izsledki niso klinično pomembni.
There were no treatment-related effects on mating, fertility or embryonic/foetal survival, and no pathological changes in the reproductive organs.
Ugotovili niso nobenih z zdravljenjem povezanih učinkov na parjenje, plodnost ali preživetje zarodka/ploda in nobenih patoloških sprememb reproduktivnih organov.
Given the short duration of increased exposure, dose reduction of the immunosuppressant based on Therapeutic Dose Monitoring is not recommended on the day of and the day after administration of IVEMEND.
Ker povečana izpostavljenost traja kratek čas, zmanjšanja odmerka imunosupresiva na dan uporabe zdravila IVEMEND in dan po njej na podlagi ugotovitev spremljanja terapevtskih odmerkov ne priporočamo.
If you get dizzy or get sleepy, avoid driving or using machines after using this medicine (see ‘Possible side effects').
Če ste po zdravljenju s tem zdravilom omotični ali zaspani, se izogibajte upravljanju vozil in strojev (glejte "Možni neželeni učinki").
† Complete response = no vomiting and no use of rescue therapy.
† Popoln odziv = brez bruhanja in brez uporabe rešilnega zdravljenja.
Ketoconazole increased the terminal half-life of oral aprepitant about 3-fold.
Ketokonazol je povečal končni razpolovni čas peroralnega aprepitanta za približno 3-krat.
In laboratory animals, fosaprepitant in non-commercial formulations caused vascular toxicity and hemolysis at concentrations below 1 mg/ml and higher, dependent on the formulation.
Pri laboratorijskih živalih je fosaprepitant v nekomercialnih pripravkih povzročil vaskularno toksičnost in hemolizo pri koncentracijah pod 1 mg/ml ali višjih, odvisno od pripravka.
Do not throw away any medicines via wastewater or house hold waste.
Zdravila ne smete odvreči v odpadne vode ali med gospodinjske odpadke.
In clinical studies, various formulations of fosaprepitant have been administered to a total of 2,687 adults including 371 healthy subjects and 2,084 patients, and 199 children and adolescents with chemotherapy induced nausea and vomiting (CINV).
V kliničnih študijah je različne farmacevtske oblike fosaprepitanta prejelo 2.687 odraslih, vključno s 371 zdravimi osebami in 2.084 bolniki, ter 199 otrok in mladostnikov s kemoterapijo povzročenima navzeo in bruhanjem (CINV - chemotherapy induced nausea and vomiting).
An alternative dose regimen that may be used with single-day chemotherapy regimens is shown in Table 4.
Alternativna shema odmerjanja, ki jo je mogoče uporabiti ob enodnevnih shemah kemoterapije, je prikazana v preglednici 4.
IVEMEND 150 mg is given as part of a combination therapy (see section 4.2).
Zdravilo IVEMEND 150 mg je namenjeno za uporabo v sklopu kombiniranega zdravljenja (glejte poglavje 4.2).
- Infusion site reactions (ISR) at or near the infusion site.
- reakcije na ali v bližini mesta infundiranja.
The recommended dose is 150 mg administered as an infusion over 20-30 minutes on Day 1, initiated approximately 30 minutes prior to chemotherapy (see section 6.6).
Priporočeni odmerek je 150 mg, ki se aplicira v obliki 20-30-minutne infuzije 1. dan, s pričetkom približno 30 minut pred kemoterapijo (glejte poglavje 6.6).
Fosaprepitant must not be used concurrently with pimozide, terfenadine, astemizole, or cisapride.
Fosaprepitanta se ne sme uporabljati skupaj s pimozidom, terfenadinom, z astemizolom ali s cisapridom.
Twelve metabolites of aprepitant have been identified in human plasma.
V humani plazmi so identificirali 12 presnovkov aprepitanta.
*Reported in patients taking a higher dose of aprepitant.
*O teh neželenih učinkih so poročali pri bolnikih, ki so jemali aprepitant v višjih odmerkih.
In vitro studies using human liver microsomes indicate that aprepitant is metabolised primarily by CYP3A4 and potentially with minor contribution by CYP1A2 and CYP2C19.
Študije in vitro s humanimi jetrnimi mikrosomi kažejo, da se aprepitant presnavlja predvsem s CYP3A4 in morda le v manjši meri s CYP1A2 in CYP2C19.
If necessary, for volumes less than 150 ml, the calculated volume can be transferred to an appropriate size bag or syringe prior to administration by infusion.
Če je izračunana količina manjša od 150 ml, jo je mogoče pred infundiranjem prenesti v vrečko ali brizgo ustrezne velikosti, če je to potrebno.
Aprepitant after fosaprepitant administration
Aprepitant po aplikaciji fosaprepitanta
**N: Number of adult patients included in the intention to treat population.
**N: Število odraslih bolnikov vključenih v populacijo z-namenom-zdravljenja.
IVEMEND should not be administered intramuscularly or subcutaneously (see section 5.3).
Zdravila IVEMEND se ne sme dajati intramuskularno ali subkutano (glejte poglavje 5.3).
• with medicines containing pimozide (used to treat psychiatric illnesses), terfenadine and astemizole (used for hay fever and other allergic conditions), cisapride (used for treating digestive problems).
• skupaj z zdravili, ki vsebujejo pimozid (uporablja se za zdravljenje psihiatričnih bolezni), terfenadin ali astemizol (uporabljata se pri zdravljenju senenega nahoda in drugih alergijskih stanj), cisaprid (uporablja se za zdravljenje prebavnih težav).
‡Complete response = no vomiting and no use of rescue therapy.
‡Popoln odziv = brez bruhanja in brez uporabe rešilnega zdravljenja.
Efficacy data in combination with other corticosteroids and 5-HT3 antagonists are limited.
Število podatkov o učinkovitosti pri sočasni uporabi z drugimi kortikosteroidi in antagonisti 5-HT3 je omejeno.
Dexamethasone should also be administered in the evenings on Days 3 and 4.
Deksametazon je treba vzeti tudi 3. in 4. dan zvečer.
Co-administration with hormonal contraceptives
Sočasna uporaba s hormonskimi kontraceptivi
What IVEMEND is and what it is used for What you need to know before you use IVEMEND How to use IVEMEND
Kaj je zdravilo IVEMEND in za kaj ga uporabljamo Kaj morate vedeti, preden boste prejeli zdravilo IVEMEND Kako uporabljati zdravilo IVEMEND Možni neželeni učinki
Hypersensitivity to the active substance or to polysorbate 80 or any of the other excipients listed in section 6.1.
Preobčutljivost na zdravilno učinkovino ali polisorbat 80 ali katero koli drugo pomožno snov, navedeno v poglavju 6.1.
All paediatric patients
Vsi pediatrični bolniki
Hepatic impairment: Fosaprepitant is metabolized in various extrahepatic tissues; therefore hepatic impairment is not expected to alter the conversion of fosaprepitant to aprepitant.
Okvara jeter: Fosaprepitant se presnavlja v številnih ekstrahepatičnih tkivih, zato ne pričakujemo, da bi okvara jeter vplivala na pretvorbo fosaprepitanta v aprepitant.
The solution for infusion is given to you by a health care professional, such as a doctor or nurse, via an intravenous infusion (a drip) approximately 30 minutes before you start the chemotherapy treatment in adults or 60 - 90 minutes before you start the chemotherapy treatment in children and adolescents.
Raztopino za infundiranje vam bo dal zdravstveni delavec, na primer zdravnik ali medicinska sestra, v obliki kapljične intravenske infuzije približno 30 minut pred začetkom kemoterapije pri odraslih ali 60-90 minut pred začetkom kemoterapije pri otrocih in mladostnikih.
Vascular disorders flushing, thrombophlebitis (predominantly, infusion-site thrombophlebitis)
Žilne bolezni zardevanje, tromboflebitis (predvsem tromboflebitis na mestu infundiranja)
• if you are allergic to fosaprepitant, aprepitant, or to polysorbate 80 or any of the other ingredients (listed in section 6).
• če ste alergični na fosaprepitant, aprepitant, polisorbat 80 ali katero koli drugo sestavino tega zdravila (navedeno v poglavju 6),
IVEMEND is incompatible with any solutions containing divalent cations (e.g., Ca
Zdravilo IVEMEND je inkompatibilno z raztopinami, ki vsebujejo dvovalentne katione (npr. Ca Mg
Concomitant administration of fosaprepitant with herbal preparations containing St. John's Wort (Hypericum perforatum) is not recommended.
Sočasne uporabe fosaprepitanta in pripravkov rastlinskega izvora, ki vsebujejo šentjanževko (Hypericum perforatum), ne priporočamo.
Co-administration with pimozide, terfenadine, astemizole or cisapride (see section 4.5).
Sočasna uporaba pimozida, terfenadina, astemizola ali cisaprida (glejte poglavje 4.5).
In adults (18 years of age and older), the recommended dose of IVEMEND is 150 mg fosaprepitant on Day 1 (day of chemotherapy).
Pri odraslih (starih 18 let ali več) je priporočeni odmerek zdravila IVEMEND 150 mg fosaprepitanta 1. dan (dan kemoterapije).
powder for solution for infusion 1 vial
prašek za raztopino za infundiranje 1 viala
Plasma concentrations of fosaprepitant are below quantifiable levels within 30 minutes of the completion of infusion.
Plazemske koncentracije fosaprepitanta so v 30 minutah po koncu infuzije manjše od določljivih vrednosti.
Immune system disorders hypersensitivity reactions including anaphylactic reactions not known
Bolezni imunskega sistema preobčutljivostne reakcije, vključno z anafilaktičnimi reakcijami neznana
At the end of the follow-up period (post-dose day 8), up to slight local subacute inflammation was noted following paravenous and intramuscular administration and additional up to moderate focal muscle degeneration/necrosis with muscle regeneration following intramuscular administration.
Po končanem obdobju spremljanja (8. dan po odmerku) so po paravenski in intramuskularni aplikaciji opazili do največ rahlo lokalno subakutno vnetje, po intramuskularni aplikaciji pa še do največ zmerno žariščno degeneracijo/nekrozo mišic z mišično regeneracijo.
These studies did not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3).
Te študije niso pokazale neposrednih ali posrednih škodljivih učinkov na nosečnost, razvoj zarodka/plodu, porod ali postnatalni razvoj (glejte poglavje 5.3).
The following information was derived from studies conducted with oral aprepitant and studies conducted with intravenous single-dose fosaprepitant co-administered with dexamethasone, midazolam, or diltiazem.
Naslednje informacije so povzete iz študij, izvedenih s peroralnim aprepitantom, in iz študij, izvedenih z enim intravenskim odmerkom fosaprepitanta v kombinaciji z deksametazonom, midazolamom ali diltiazemom.
Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older.
Preprečevanje navzee in bruhanja, povezanih z zelo in zmerno emetogeno kemoterapijo rakavih bolezni pri odraslih in pediatričnih bolnikih, starih 6 mesecev ali več.
The majority of severe ISRs, including thrombophlebitis and vasculitis, were reported with concomitant vesicant (e.g., anthracycline-based) chemotherapy administration, particularly when associated with extravasation.
O večini hudih reakcij na mestu infundiranja, vključno s tromboflebitisom in vaskulitisom, so poročali pri sočasni uporabi kemoterapije z vezikanti (na primer na osnovi antraciklinov), še posebej v povezavi z ekstravazacijo.
The brain has a specific area that controls nausea and vomiting.
V možganih je določeno področje, ki nadzira navzeo (siljenje na bruhanje) in bruhanje.
Effect of fosaprepitant on the pharmacokinetics of other active substances CYP3A4 inhibition
Vpliv fosaprepitanta na farmakokinetiko drugih zdravilnih učinkovin Zaviranje CYP3A4
Due to modest decreases in protein binding of aprepitant in patients with renal disease, the AUC of pharmacologically active unbound aprepitant was not significantly affected in patients with renal impairment compared with healthy subjects.
Zaradi nekoliko manjše vezave aprepitanta na beljakovine pri bolnikih z okvaro ledvic, se AUC farmakološko aktivnega nevezanega zdravila v primerjavi z zdravimi preiskovanci ni bistveno spremenila.